Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Q-linea AB (publ)
  6. News
  7. Summary
    QLINEA   SE0011527845

Q-LINEA AB (PUBL)

(QLINEA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Q linea : Commercial evaluation of the ASTar system in Europe started

06/04/2021 | 05:36am EDT

Q-linea AB (publ) (OMX: QLINEA), a diagnostics company focused on developing and delivering solutions to diagnose infectious diseases accurately and rapidly, today announces the start of commercial evaluation of the fully automated ASTar® Instrument and first ASTar Consumable kit, delivering rapid antimicrobial susceptibility results for gram-negative bacteria, including fastidious, directly from positive blood cultures.

“We are happy to announce that we, within a month of the CE-mark, have started the commercial evaluation of ASTar in Europe with the first system installation. It shows the dedication we have from Thermo Fisher Scientific and that all the preparations from both organizations have paid off. This is our first step in the commercial launch strategy for ASTar to support long-term successful commercialization. Thermo Fisher Scientific has a dedicated sales, marketing and service organization to support ASTar and I think this is very positive,” said Jonas Jarvius, CEO at Q-linea.

The ASTar Instrument and ASTar BC G- Kit offer the broadest combination of antimicrobials and dilution ranges in a single analysis for gram-negative bacteria. The test enables the analysis of both, fastidious and non-fastidious bacteria, for rapid and comprehensive results that support optimal treatment decisions.

If you would like to receive additional information regarding ASTar please contact Q-linea for the Swedish market www.qlinea.com/request-consultation and Thermo Fisher Scientific for other European countries www.thermofisher.com/se/en/home/global/forms/industrial/rapid-antimicrobial-susceptibility-testing.html.

The ASTar® Instrument and ASTar® BC G- Kit are CE-marked but not FDA 510(k)-cleared and not available for sale in the U.S.

© Modular Finance, source Nordic Press Releases

Stocks mentioned in the article
ChangeLast1st jan.
Q-LINEA AB (PUBL) -1.02% 155.2 Delayed Quote.-8.71%
THERMO FISHER SCIENTIFIC 1.17% 540.01 Delayed Quote.14.60%
All news about Q-LINEA AB (PUBL)
07/15Q-Linea AB Reports Earnings Results for the Second Quarter Ended June 30, 202..
CI
07/08Q LINEA : Invitation to presentation of Q-linea's Interim report Q2-2021 on July..
AQ
06/30Q LINEA : Change in the number of shares and votes in Q-linea AB
AQ
06/10Q LINEA : has carried out a directed issue of 2.2 million shares, raising gross ..
AQ
06/10Q LINEA : announces intention to carry out a directed share issue
AQ
06/07Q LINEA : initiates US 510(k) clinical study for ASTar
AQ
06/07Q-linea AB Initiates US 510(k) Clinical Study for ASTar
CI
06/04Q LINEA : Commercial evaluation of the ASTar system in Europe started
AQ
05/25Q LINEA : Bulletin from annual general meeting in q-linea ab (publ)
AQ
05/05Q-Linea AB Publ Reports Earnings Results for the First Quarter Ended March 31..
CI
More news
Financials
Sales 2021 95,3 M 11,1 M 11,1 M
Net income 2021 -168 M -19,5 M -19,5 M
Net cash 2021 56,7 M 6,59 M 6,59 M
P/E ratio 2021 -26,3x
Yield 2021 -
Capitalization 4 533 M 527 M 527 M
EV / Sales 2021 47,0x
EV / Sales 2022 12,0x
Nbr of Employees 118
Free-Float 90,5%
Chart Q-LINEA AB (PUBL)
Duration : Period :
Q-linea AB (publ) Technical Analysis Chart | QLINEA | SE0011527845 | MarketScreener
Technical analysis trends Q-LINEA AB (PUBL)
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Last Close Price 155,20 SEK
Average target price 185,00 SEK
Spread / Average Target 19,2%
EPS Revisions
Managers and Directors
Jonas Sven Peter Jarvius President & Chief Executive Officer
Anders Lundin Chief Financial Officer & Head-Investor Relations
Erika Elisabeth Kjellberg-Eriksson Chairman
Tiziana di Martino Chief Medical Officer
Nils-Peter Kristensen Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
Q-LINEA AB (PUBL)-8.71%527
EXACT SCIENCES CORPORATION-18.61%18 543
GUARDANT HEALTH, INC.-14.80%11 103
BGI GENOMICS CO., LTD.-12.57%7 130
INVITAE CORPORATION-33.05%5 593
ADAPTIVE BIOTECHNOLOGIES CORPORATION-38.00%5 144